Overview
GOSS market data
Price History
GOSS price chart
Valuation & Profitability
No Valuation Data Yet
Alpha Vantage and Twelve Data both returned no valuation metrics for GOSS. Check back after the next daily valuation refresh — this symbol may be new, delisted, or temporarily unavailable from both providers.
Company news
8-K filing — Gossamer Bio, Inc. (GOSS)SEC EDGAR · Jul 15, 2026, 12:39 AM
HC Wainwright & Co. Maintains Buy on Gossamer Bio, Lowers Price Target to $2Benzinga · Jun 25, 2026, 4:35 PM
Gossamer Bio Completes Debt Exchange, Converting $181M Of 2027 Notes Into New Secured Notes And EquityBenzinga · Jun 17, 2026, 12:20 PM
Gossamer Bio, Inc. (GOSS) Faces Securities Class Action Amid 80% Drop On Phase 3 PROSERA Trial Failure– HBSSGlobenewswire Inc · May 29, 2026, 7:15 PM
GOSSAMER BIO DEADLINE MONDAY JUNE 1st: Bragar Eagel & Squire, P.C. Urges Gossamer Bio, Inc. (NASDAQ:GOSS) Investors with Large Losses to Contact the Firm Before Monday June 1stGlobenewswire Inc · May 29, 2026, 5:15 PM
HC Wainwright & Co. Reiterates Buy on Gossamer Bio, Maintains $5 Price TargetBenzinga · May 26, 2026, 10:17 AM
Pulmonary Arterial Hypertension Clinical Trial Pipeline Gains Momentum: 50+ Companies Lead the Charge in Pioneering New Treatments | DelveInsightGlobenewswire Inc · May 19, 2026, 5:15 PM
Gossamer Bio, Inc. (GOSS) Faces Securities Class Action Amid 80% Drop On Phase 3 PROSERA Trial Failure – Hagens BermanGlobenewswire Inc · May 19, 2026, 1:15 PM
Gossamer Bio Reports Q1 2026 Results: Full Earnings Call TranscriptBenzinga · May 18, 2026, 2:35 PM
Gossamer Bio Launches Exchange Offer For $72M New 7.5% Notes, Up To 317.6M Shares/Prefunded Warrants, Plus Early Tender Purchase WarrantsBenzinga · May 18, 2026, 11:25 AM